Orthofix Medical (OFIX) Scheduled to Post Quarterly Earnings on Thursday

Orthofix Medical (NASDAQ:OFIX) will announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Orthofix Medical (NASDAQ:OFIX) last posted its earnings results on Tuesday, August 6th. The medical device company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.58). The firm had revenue of $198.62 million during the quarter, compared to the consensus estimate of $195.75 million. Orthofix Medical had a negative return on equity of 20.68% and a negative net margin of 15.61%. On average, analysts expect Orthofix Medical to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Orthofix Medical Stock Performance

Shares of OFIX stock opened at $17.71 on Wednesday. Orthofix Medical has a one year low of $9.57 and a one year high of $17.71. The company has a market cap of $675.99 million, a P/E ratio of -5.55 and a beta of 1.05. The firm has a 50-day moving average of $16.15 and a 200-day moving average of $15.15. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.48 and a quick ratio of 1.13.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.